This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Heng Xie, M.D., M.P.H., Ph.D., NCI, Phone: 301-496-8866 Email: XieHe@mail.nih.gov
This FOA encourages research activities in the broad areas of etiology and etiologic mechanism(s) of liver cancer, include, but are not limited to: (a) identification of viral and host factors in initiation of HCC, (b) examination of the development of HCC in the sequelae of HIV infection(c) development of animal models and in vitro virus cultivation methods; (d) development of prevention and control strategies, including chemoprevention; (e), validation of markers; (f) preclinical or clinical trials of promising agents; and (g) imaging studies for diagnosis and intervention.
Research topics include research on the treatment and diagnosis of HCC, including
Conduct of therapeutic clinical trials designed to evaluate novel anticancer agents with distinctive molecular targets, as well as therapeutic combinations of novel agents;
Conduct of clinical translational research on promising biomarkers for determining prognosis and/or predicting response(s) to therapy;
Development of functional imaging techniques that can reliably distinguish HCC from benign hepatic lesions;
Conduct of clinical trials designed to evaluate the role, efficacy, and safety of image-guided local therapies, such as radio-frequency thermal ablation (RFA), particularly in relation to use of liver transplantation for patients with small HCC;
Test of the utility of imaging modalities to evaluate pharmacokinetics and pharmacodynamics of targeted therapies;
Evaluation of the use of imaging as a surrogate marker or endpoint for drug activity in therapeutic clinical trials; and
Development of novel imaging approaches that can be used as diagnostic tools for early detection of HCC.
Mark Scheideler, Ph.D., Phone: 301-496-1779, Email: email@example.com
This FOA issued by participating institutes of the National Institutes of Health, encourages research grant applications from institutions/ organizations that propose to develop new small molecule probes for investigating biological function in the nervous system via the application of advanced medicinal chemistry and the biological testing of compounds. Eligible investigators will have identified probe candidates via screening of small molecule collections, using in vitro assays of biological activity developed to interrogate these collections, and be able to show that the structural features of these small molecules are related to their biological activity. Proposals should nominate small molecule probe candidates from distinct structural series for the further, iterative design and testing of analogues in structure-activity relationship studies, using in vitro assays of biological function adapted to the medium throughput screening requirements of this work. These studies should have the goal of developing a small molecule probe possessing the attributes (eg: affinity, selectivity, activity) required for its use in future pharmacological studies proposed by the investigator. Applicants are strongly encouraged to utilize publicly available cheminformatic capabilities for the acquisition of compounds, and semi-custom synthesis of analogues.
Proposals should include both a biological and chemical component. The biological component should include a plan of in vitro and, when appropriate, limited in vivo assays, each capable of measuring the activity of a test compound towards an attribute that the "hit" compound proposed as a starting point for modification possesses, and that needs to be further enhanced or eliminated by redesign of the "hit".
Maren R Laughlin, Ph.D., NIDDK, Phone: 301-594-8802, Email: firstname.lastname@example.org
This Funding Opportunity Announcement (FOA) is a call for the application of imaging and other non- or minimally-invasive technologies to detect, characterize, diagnose, identify persons with predisposition to, or monitor treatment of diseases of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Also needed are new, robust surrogate markers for clinical trial endpoints, and new ways to characterize normal and pathological tissues in vivo. Diseases of interest include type 1 and 2 diabetes; acute and chronic kidney disease, liver, urologic, hematologic, digestive, endocrine, and metabolic diseases and their complications; obesity; obesity-related hypertension, hypertension, renal and vascular disorders leading to hypertension. Applicable techniques include molecular imaging and functional imaging approaches, imaging methods with high spatial, chemical or time resolution, metabolomics, proteomics, genomics, or new spectroscopic or sensor array technologies for monitoring metabolic or physiological events.
Yong Yao, Ph.D., NIH Roadmap Molecular Libraries and Imaging, Phone: (301) 443-6102, Email: email@example.com
The NIH Molecular Libraries Roadmap Initiative wishes to solicit HTS assay applications from investigators who have the interest and capability to work with the Molecular Libraries Probe Production Centers Network (MLPCN) in support of chemical probe development. This FOA promotes discovery and development of new chemical probes as research tools for use by scientists in both the public and private sector to advance the understanding of biological functions and disease mechanisms.
See full description in NIH Guide:PAR-09-129
Sonia Jakowlew, Ph.D., Phone: 301-496-8580, Email: firstname.lastname@example.org
The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.
See full description in NIH Guide:PAR-09-089
Shannon M. Lemrow, Ph.D., NCI, Phone: 301-496-8580, Email: email@example.com
See full description in NIH Guide:PAR-09-088
The goal of the Mentored Patient-Oriented Research Career Development Award (K23) program is to ensure a future cadre of well-trained scientists working in POR areas who will become competitive for NIH research project (R01) grant support. The specific objectives of the Mentored Patient-Oriented Research Career Development Award are to:
1)encourage research-oriented clinicians to develop independent research skills and gain experience in advanced methods and experimental approaches needed to become an independent investigator conducting patient-oriented research; 2) increase the pool of clinical researchers who can conduct patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to clinical settings; 3) support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research.
For the purposes of this award, Patient-Oriented Research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials, and; 4) the development of new technologies. Studies falling under Exemption 4 for human subjects research are not included in this definition.
See full description in NIH Guide:PA-09-043
Dorkina Myrick, M.D., Ph.D. (NCI), Phone: 301-496-8580, Email: Myrick@mail.nih.gov
The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).
An award provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (http://grants.nih.gov/grants/guide/contacts/PA-09-042_contacts.html).
See full description in NIH Guide:PAR-09-042
Andrew Freedman, Ph.D., NCI, Phone: 301-435-6819, Email: firstname.lastname@example.org
The purpose is to invite applications for health services research addressing utilization of emerging cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.
Lester Gorelic, Ph.D., Tel: (301) 496-8580; Email: email@example.com
This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).
Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.See full description in NIH Guide:PAR-08-120